Macro Trials Company Profile

Background

Macro Trials, established in 2021 and headquartered in Los Angeles, California, is a precision research clinical platform dedicated to transforming the clinical trial landscape for high-value therapeutics. The company's mission is to expedite the delivery of life-saving treatments by enhancing research velocity and ensuring equitable access to care.

Key Strategic Focus

Macro Trials focuses on:

Accelerating Clinical Trials: Utilizing a digitally powered infrastructure to streamline the design, planning, and execution of clinical trials, thereby reducing time-to-market for high-value therapeutics.

Enhancing Diversity and Inclusion: Implementing a distributed "hub-and-spoke" model to conduct trials across various settings, including in-person and decentralized environments. This approach empowers a diverse range of physician groups and independent clinicians to participate in research, leading to more representative and equitable patient enrollment.

Leveraging Real-World Evidence (RWE): Aggregating and synthesizing proprietary RWE to generate valuable longitudinal patient records, supporting comprehensive therapeutic research and development.

Financials and Funding

In June 2023, Macro Trials secured $6 million in seed funding to support product development, expand clinical trial infrastructure, and scale study execution capabilities. The funding round was led by MBX Capital, with participation from INITIATE Ventures, Healthy VC, Inflect Health, and Village Global.

Pipeline Development

Macro Trials is actively involved in conducting clinical trials for high-value therapeutics across various therapeutic areas. The company's platform is designed to efficiently bring life-saving treatments to market at scale, with a focus on increasing research velocity and providing equitable access to care.

Technological Platform and Innovation

Macro Trials distinguishes itself through:

Digitally Powered Infrastructure: A comprehensive platform that facilitates real-time data collection and management, enhancing the efficiency and accuracy of clinical trials.

Distributed "Hub-and-Spoke" Model: This model enables the company to conduct trials in diverse settings, from traditional in-person to decentralized environments, thereby broadening patient recruitment and participation.

Proprietary Real-World Evidence as a Service (RWEaaS): Offering a service that supports life sciences companies in all aspects of therapeutic research, development, and commercialization by providing valuable real-world data.

Leadership Team

Iana Dimkova: Co-Founder and Chief Executive Officer.

Babak Azizzadeh, MD: Co-Founder, President, and Board Member.

Jonathan Cabin, MD: Co-Founder and Chief Medical Officer.

Alex Trombetta: Co-Founder and Vice President of Strategy & Product.

Leadership Changes

In March 2021, Daniel Perez was appointed Chief Executive Officer, transitioning from his previous role as Chief Operating Officer. Concurrently, Jonathan Cabin, MD, moved from CEO to Chief Medical Officer.

Competitor Profile

Market Insights and Dynamics

The clinical trial industry is experiencing significant growth, driven by the increasing development of high-value therapeutics. However, challenges such as high failure rates, substantial costs, and underrepresentation of diverse populations persist.

Competitor Analysis

Key competitors include:

Clinical Ink: Provides e-source solutions for clinical trials, focusing on electronic data capture and management.

SonderMind: Develops a platform connecting clients with local, in-network therapists, emphasizing mental health services.

Clarest Health: Offers pharmacy services, including medication management and patient support programs.

CareMetx: Specializes in patient-centric services and technology solutions for specialty therapies.

Strategic Collaborations and Partnerships

Macro Trials has partnered with the Los Angeles LGBT Center to implement transgender awareness and sensitivity training for clinical research personnel. This collaboration aims to widen inclusion efforts and create career opportunities for the transgender community.

Operational Insights

Macro Trials' patient-centric model and generation of new data aim to improve the R&D landscape, making safer, better drugs more accessible.

Strategic Opportunities and Future Directions

Macro Trials plans to:

Expand Clinical Trial Infrastructure: Broaden its reach across geographies and therapeutic areas to meet the growing demand for high-value therapeutics.

Enhance Technological Capabilities: Continue developing its digital infrastructure to further streamline clinical trial processes and data management.

Promote Diversity and Inclusion: Strengthen efforts to ensure equitable access to clinical trials, reflecting the diversity of the impacted population.